StockIQ.techBioMarin Pharmaceutical Inc. (BMRN) Stock Analysis
Free AI-powered analysis and research for BioMarin Pharmaceutical Inc. stock
Sector: Healthcare
BMRN snapshot
Data as of 4 Nov 2026 close. Updated daily.
BioMarin Pharmaceutical Inc. scores 51/100 on StockIQ's model, which reads as mixed signals overall. The price is below its 200-day average and at 35% of its 52-week range, up 8.3% over the past year. Latest reported figures show a profit margin of 2.1%, return on equity of 1.2% and revenue growth of +19.9%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bullish: +8
- High P/E (154.4): -10
- Strong Revenue Growth (19.9%): +8
- Weak Profit Margin (2.1%): -8
- Strong Liquidity (2.39 Current Ratio): +8
- Weak ROE (1.2%): -6
- Below MA200: -4
- Up Over 1 Year (+8.3%): +3
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BMRN report
BioMarin Pharmaceutical Inc. (BMRN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BMRN Now →📰 Latest Update
BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
Wed, November 4, 2026 at 3:02 AM UTC 2 min read
BioMarin Pharmaceutical Inc (BMRN) reported its first-ever quarterly revenue exceeding $1 billion, marking a 32% year-over-year increase in Q3 2026. The metabolic conditions segment saw significant growth, with revenues from GALAFOLD and POMBILITI + OPFOLDA rising 10% and 58%, respectively. Despite strong performance, the company adjusted its full-year revenue guidance to $3.8-$3.9 billion due to deferred international orders and disruptions from the ongoing Middle East conflict.